Avadel Historical Cash Flow
| AVDL Stock | USD 11.07 0.16 1.42% |
Analysis of Avadel Pharmaceuticals cash flow over time is an excellent tool to project Avadel Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 23.2 M or Total Cashflows From Investing Activities of 54.4 M as it is a great indicator of Avadel Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Avadel Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Avadel Pharmaceuticals is a good buy for the upcoming year.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. About Avadel Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Avadel balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Avadel's non-liquid assets can be easily converted into cash.
Avadel Pharmaceuticals Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Avadel Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Avadel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. At this time, Avadel Pharmaceuticals' Other Cashflows From Investing Activities is quite stable compared to the past year. Stock Based Compensation is expected to rise to about 21.4 M this year, although the value of Free Cash Flow is projected to rise to (44.6 M).
Avadel Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Avadel Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Avadel Pharmaceuticals cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (1.4M) | (2.8M) | (30K) | (9.5M) | (9.2M) | (8.8M) | |
| Change In Cash | 61.9M | (21.0M) | 23.3M | (42.8M) | 20.2M | 21.2M | |
| Free Cash Flow | (48.8M) | (77.3M) | (71.0M) | (128.5M) | (46.9M) | (44.6M) | |
| Change In Working Capital | (8.1M) | 3.7M | 24.5M | (3.0M) | (20.3M) | (19.3M) | |
| Begin Period Cash Flow | 9.8M | 71.7M | 50.7M | 74.0M | 31.2M | 23.2M | |
| Total Cashflows From Investing Activities | (69.7M) | 56.9M | 79.7M | (50.1M) | 51.8M | 54.4M | |
| Other Cashflows From Financing Activities | (69.7M) | 263K | (10.8M) | 27.9M | 6.7M | 7.1M | |
| Depreciation | 1.7M | 815K | 1.5M | 1.8M | 2.7M | 4.6M | |
| Other Non Cash Items | (44.9M) | 2.3M | 8.1M | 17.2M | (828K) | (786.6K) | |
| Capital Expenditures | 20.2M | 29K | 98K | 26K | 716K | 0.0 | |
| Total Cash From Operating Activities | (48.7M) | (77.3M) | (70.3M) | (128.5M) | (46.9M) | (44.6M) | |
| Net Income | 7.0M | (77.3M) | (137.5M) | (160.3M) | (48.8M) | (46.4M) | |
| Total Cash From Financing Activities | 179.7M | 263K | 14.5M | 135.3M | 16.0M | 26.4M | |
| End Period Cash Flow | 71.7M | 50.7M | 74.0M | 31.2M | 51.4M | 29.2M | |
| Other Cashflows From Investing Activities | 38.8M | 25.5M | 16.5M | 80.4M | 92.5M | 97.1M | |
| Change To Liabilities | 5.0M | (16.0M) | 5.1M | (3.1M) | (2.8M) | (2.7M) | |
| Change To Account Receivables | 8.3M | 2.8M | 30K | (10.2M) | (22.0M) | (20.9M) | |
| Sale Purchase Of Stock | (27.6M) | 118K | 179.7M | 263K | 302.5K | 287.3K | |
| Stock Based Compensation | 3.0M | 8.9M | 7.0M | 15.8M | 20.4M | 21.4M | |
| Investments | (95.1M) | 40.5M | 79.7M | (50.1M) | 51.8M | 54.4M | |
| Change To Operating Activities | (18.6M) | (18.5M) | (537K) | 27.6M | 31.8M | 33.4M | |
| Change To Netincome | (6.1M) | (50.1M) | (5.5M) | 35.1M | 31.6M | 33.2M | |
| Cash And Cash Equivalents Changes | (7.2M) | 371K | 61.2M | (20.1M) | (23.1M) | (22.0M) | |
| Cash Flows Other Operating | (49.8M) | (16.1M) | (4.8M) | (1.6M) | (1.5M) | (1.6M) | |
| Issuance Of Capital Stock | 179.7M | 263K | 25.3M | 146.1M | 9.3M | 8.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth 0.932 | Return On Assets | Return On Equity |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.